FDA — authorised 31 March 1986
- Status: approved
🇺🇸 Elimite in United States
FDA authorised Elimite on 31 March 1986
Marketing authorisations
FDA — authorised 2 May 1990
- Application: NDA019918
- Marketing authorisation holder: MEDTECH PRODUCTS
- Local brand name: NIX
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 4 September 2001
- Application: ANDA074806
- Marketing authorisation holder: ACTAVIS LABS
- Indication: Manufacturing (CMC)
- Status: approved
FDA — authorised 20 December 2001
- Application: ANDA076090
- Marketing authorisation holder: PERRIGO NEW YORK
- Local brand name: PERMETHRIN
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 21 April 2003
- Application: ANDA076369
- Marketing authorisation holder: PADAGIS ISRAEL
- Status: approved
FDA — authorised 3 April 2019
- Application: ANDA211303
- Marketing authorisation holder: ENCUBE ETHICALS
- Status: approved
FDA — authorised 1 August 2023
- Application: ANDA209732
- Marketing authorisation holder: DR REDDYS LABS EU
- Local brand name: PERMETHRIN
- Indication: CREAM — TOPICAL
- Status: approved
Elimite in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Elimite approved in United States?
Yes. FDA authorised it on 31 March 1986; FDA authorised it on 2 May 1990; FDA authorised it on 4 September 2001.
Who is the marketing authorisation holder for Elimite in United States?
Marketing authorisation holder not available in our data.